share_log

Short Interest in Aziyo Biologics, Inc. (NASDAQ:AZYO) Drops By 55.6%

Short Interest in Aziyo Biologics, Inc. (NASDAQ:AZYO) Drops By 55.6%

對阿齊約生物製劑公司的短期興趣 (納斯達克:AZYO) 下降 55.6%
kopsource ·  2022/12/15 10:12

Aziyo Biologics, Inc. (NASDAQ:AZYO – Get Rating) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 3,200 shares, a decline of 55.6% from the November 15th total of 7,200 shares. Based on an average daily volume of 21,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short.

阿齊約生物股份有限公司(納斯達克：AZYO-GET評級)在11月份看到空頭股數的銷售額大幅下降。截至11月30日，空頭股數共有3200股，較11月15日的7200股下降了55.6%。以日均成交量21,000股計算，目前天數與回補比率為0.2天。目前，該公司0.1%的股份被賣空。

Aziyo Biologics Price Performance

Aziyo生物製品價格表現

NASDAQ:AZYO opened at $3.64 on Thursday. The firm has a market cap of $50.14 million, a PE ratio of -1.28 and a beta of -0.54. Aziyo Biologics has a 12 month low of $3.51 and a 12 month high of $9.01. The company has a quick ratio of 0.83, a current ratio of 1.09 and a debt-to-equity ratio of 1.34. The company's 50-day moving average price is $6.83 and its two-hundred day moving average price is $6.71.

納斯達克：AZYO週四開盤報3.64美元。該公司市值為5,014萬美元，市盈率為-1.28，貝塔係數為-0.54。Aziyo Biologics的12個月低點為3.51美元，12個月高位為9.01美元。該公司的速動比率為0.83，流動比率為1.09，債務權益比率為1.34。該公司的50日移動均線價格為6.83美元，200日移動均線價格為6.71美元。

Get
到達
Aziyo Biologics
Aziyo生物製品
alerts:
警報：

Aziyo Biologics (NASDAQ:AZYO – Get Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.07). The firm had revenue of $12.39 million during the quarter, compared to analyst estimates of $12.20 million. Aziyo Biologics had a negative net margin of 77.08% and a negative return on equity of 1,819.23%. On average, equities analysts anticipate that Aziyo Biologics will post -2.63 EPS for the current fiscal year.

阿齊約生物(納斯達克：AZYO-GET Rating)最近一次發佈季度收益報告是在11月14日(星期一)。該公司公佈了該季度每股收益(0.73美元)，低於分析師普遍預期的(0.66美元)和(0.07美元)。該公司本季度營收為1239萬美元，而分析師預期為1220萬美元。Aziyo Biologics的淨利潤率為負77.08%，淨資產回報率為負1819.23%。股票分析師平均預計，Aziyo Biologics本財年的每股收益將達到2.63歐元。

Insider Transactions at Aziyo Biologics

Aziyo Biologics的內幕交易

In related news, Director Highcape Capital, L.P. acquired 735,000 shares of the company's stock in a transaction dated Monday, December 5th. The shares were bought at an average price of $4.75 per share, for a total transaction of $3,491,250.00. Following the acquisition, the director now owns 5,597,604 shares in the company, valued at approximately $26,588,619. The transaction was disclosed in a legal filing with the SEC, which is available through
相關新聞，董事在12月5日星期一的交易中收購了735,000股該公司股票。這些股票是以每股4.75美元的平均價格購買的，總交易額為3,491,250.00美元。收購完成後，董事現在擁有該公司5597,604股，價值約26,588,619美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過
this hyperlink
此超鏈接
. In related news, Director Highcape Capital, L.P. acquired 735,000 shares of the company's stock in a transaction dated Monday, December 5th. The shares were bought at an average price of $4.75 per share, for a total transaction of $3,491,250.00. Following the acquisition, the director now owns 5,597,604 shares in the company, valued at approximately $26,588,619. The transaction was disclosed in a legal filing with the SEC, which is available through
。相關新聞，董事在12月5日星期一的交易中收購了735,000股該公司股票。這些股票是以每股4.75美元的平均價格購買的，總交易額為3,491,250.00美元。收購完成後，董事現在擁有該公司5597,604股，價值約26,588,619美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過
this hyperlink
此超鏈接
. Also, CFO Matthew Ferguson bought 22,000 shares of the firm's stock in a transaction dated Monday, December 5th. The shares were acquired at an average price of $4.65 per share, for a total transaction of $102,300.00. Following the completion of the transaction, the chief financial officer now owns 45,217 shares in the company, valued at approximately $210,259.05. The disclosure for this purchase can be found
。此外，首席財務官馬修·弗格森在12月5日星期一的交易中購買了22,000股該公司的股票。這些股票是以每股4.65美元的平均價格收購的，總交易額為102,300.00美元。交易完成後，首席財務官現在擁有該公司45,217股，價值約210,259.05美元。關於這次購買的披露可以找到
here
這裏
. In the last 90 days, insiders have purchased 765,000 shares of company stock worth $3,625,030. 39.90% of the stock is currently owned by company insiders.
。在過去的90天裏，內部人士購買了76.5萬股公司股票，價值3,625,030美元。公司內部人士目前持有該公司39.90%的股份。

Hedge Funds Weigh In On Aziyo Biologics

對衝基金買入Aziyo Biologics

A hedge fund recently raised its stake in Aziyo Biologics stock. Endurant Capital Management LP lifted its stake in shares of Aziyo Biologics, Inc. (NASDAQ:AZYO – Get Rating) by 3.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,109,479 shares of the company's stock after purchasing an additional 33,839 shares during the period. Aziyo Biologics makes up about 1.7% of Endurant Capital Management LP's investment portfolio, making the stock its 16th biggest position. Endurant Capital Management LP owned approximately 8.18% of Aziyo Biologics worth $6,601,000 as of its most recent filing with the Securities and Exchange Commission. 24.52% of the stock is currently owned by hedge funds and other institutional investors.

一家對衝基金最近增持了Aziyo Biologics股票。耐久資本管理有限公司(Endurant Capital Management LP)最近向美國證券交易委員會(Securities And Exchange Commission)披露的信息顯示，該公司第一季度增持了Aziyo Biologics，Inc.(納斯達克代碼：AZYO-GET Rating)的股份3.1%。該機構投資者持有該公司1,109,479股股票，在此期間又購買了33,839股。Aziyo Biologics在Enurant Capital Management LP的投資組合中約佔1.7%，使該股成為其第16大頭寸。截至最近向美國證券交易委員會提交的文件，耐久資本管理有限公司擁有Aziyo Biologics約8.18%的股份，價值6,601,000美元。該公司24.52%的股票目前由對衝基金和其他機構投資者持有。

Analyst Upgrades and Downgrades

分析師升級和下調評級

AZYO has been the topic of several recent research reports. Truist Financial lifted their target price on shares of Aziyo Biologics from $8.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, November 16th. Piper Sandler lifted their target price on shares of Aziyo Biologics from $9.00 to $10.50 and gave the company an "overweight" rating in a research report on Tuesday, November 15th.

AZYO是最近幾份研究報告的主題。Truist Financial在11月16日(週三)的一份研究報告中將Aziyo Biologics的股票目標價從8.00美元上調至10.00美元，並給予該公司“買入”評級。派珀·桑德勒在11月15日週二的一份研究報告中將Aziyo Biologics的股票目標價從9.00美元上調至10.50美元，並給予該公司“增持”評級。

Aziyo Biologics Company Profile

Aziyo生物製品公司簡介

(Get Rating)

(獲取評級)

Aziyo Biologics, Inc, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device.

Aziyo Biologics，Inc.是一家再生醫學公司，專注於再生醫療產品的開發，以滿足植入式電子設備/心血管、矯形/脊柱修復和軟組織重建市場。它提供CanGaroo，它將信封與抗生素結合在一起，旨在降低電子設備手術植入後的感染風險。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on Aziyo Biologics (AZYO)
  • Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
  • Is Enterprise Products Partners Fairly Valued?
  • Will WhatsApp Partnership Boost MercadoLibre's Earnings?
  • 3 Mid-Caps That Could Double in 2023
  • Mullen Automotive Shares Jump After Signing New Partner
  • 免費獲取StockNews.com關於Aziyo生物製品的研究報告(AZYO)
  • 通貨膨脹和能源危機是兩列相撞的貨運列車--以下是如何做好準備的
  • 企業產品合作伙伴是否得到公平評價？
  • WhatsApp合作伙伴關係是否會提振MercadoLibre的收益？
  • 2023年中型股可能翻一番
  • 馬倫汽車簽署新合作伙伴後股價上漲

Receive News & Ratings for Aziyo Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aziyo Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

獲得Aziyo生物製品日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aziyo Biologics和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論